# Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

> **NCT02278458** · PHASE1 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** icotinib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02278458
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2016-01
- **Final completion:** 2016-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2015-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02278458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02278458, "Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02278458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*